Scotia
Article Abstract:
Scotia Holdings is a drug discovery company which is offering a convertible bond that represents an investment opportunity, although biotechnology companies have fallen out of fashion. The company has lost money since its stock flotation in 1993. The bonds offer a fixed interest paid twice a year at 8.5% yearly. The company plans to seek regulatory approval for its Foscan anti-cancer treatment in Europe and the US in 1999. The company has also produced a food additive called Olibra which functions as an appetite suppressant.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Scotia
Article Abstract:
Scotia has a promising product in Foscan which could bring marketing royalties, though there is no guarantee that it will achieve regulatory approval.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Theratase
Article Abstract:
Theratase supplies enzymes and biochemicals and has undergone a recovery, though there are costs linked to preference share repayments.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Second time lucky. Being there. Porn goes public
- Abstracts: Broadcast Connection. Ivanhoe Broadcast News. Levenson PR
- Abstracts: Techno mecca. Occupational hazards. Will you be able to face your bank manager?
- Abstracts: Uncivil action. Preparing for the worst. Insurers build export credit share
- Abstracts: Switching 401(k) service providers. Tracking pay at Internet subs. Too much of a good thing